UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

level3

	Fusion Gene Summary
	Fusion Gene Sample Information
	Fusion ORF Analysis
	Fusion Amino Acid Sequences
	Fusion Protein Functional Features
	Fusion Protein Structure
	pLDDT scores
	Ramachandran Plot of Fusion Protein Structure
	Potential Active Site Information
	Potentially Interacting Small Molecules through Virtual Screening
	Biochemical Features of Small Molecules with ADME
	Drug Toxicity Information
	Fusion Protein-Protein Interaction
	Related drugs with this fusion protein
	Related disease with this fusion protein

Fusion Protein:KAT6A-EP300

Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: KAT6A-EP300
	FusionPDB ID: 41203
	FusionGDB2.0 ID: 41203
		Hgene	Tgene
	Gene symbol	KAT6A	EP300
	Gene ID	7994	2033
	Gene name	lysine acetyltransferase 6A	E1A binding protein p300
	Synonyms	ARTHS\|MOZ\|MRD32\|MYST-3\|MYST3\|RUNXBP2\|ZC2HC6A\|ZNF220	KAT3B\|MKHK2\|RSTS2\|p300
	Cytomap	8p11.21	22q13.2
	Type of gene	protein-coding	protein-coding
	Description	histone acetyltransferase KAT6AK(lysine) acetyltransferase 6AMOZ, YBF2/SAS3, SAS2 and TIP60 protein 3MYST histone acetyltransferase (monocytic leukemia) 3histone acetyltransferase MYST3monocytic leukemia zinc finger proteinrunt-related transcription	histone acetyltransferase p300E1A-associated protein p300E1A-binding protein, 300kDhistone butyryltransferase p300histone crotonyltransferase p300p300 HATprotein 2-hydroxyisobutyryltransferase p300protein propionyltransferase p300
	Modification date	20200313	20200329
	UniProtAcc	Q92794	Q09472
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000406337, ENST00000265713, ENST00000396930, ENST00000485568,	ENST00000263253,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	26 X 32 X 13=10816	22 X 26 X 8=4576
	# samples	42	25
	** MAII score	log2(42/10816*10)=-4.68663391861606 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(25/4576*10)=-4.1940870521163 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context (manual curation of fusion genes in FusionPDB)	PubMed: KAT6A [Title/Abstract] AND EP300 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)
Anticipated loss of major functional domain due to fusion event.	KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target by not retaining the major functional domain in the partially deleted in-frame ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF. KAT6A-EP300 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	KAT6A	GO:0006473	protein acetylation	23431171
Hgene	KAT6A	GO:0016573	histone acetylation	11742995\|17925393
Hgene	KAT6A	GO:0030099	myeloid cell differentiation	11742995
Hgene	KAT6A	GO:0043966	histone H3 acetylation	16387653
Hgene	KAT6A	GO:0045892	negative regulation of transcription, DNA-templated	11742995
Hgene	KAT6A	GO:0045893	positive regulation of transcription, DNA-templated	11742995\|11965546\|18794358
Tgene	EP300	GO:0000122	negative regulation of transcription by RNA polymerase II	10733570
Tgene	EP300	GO:0001666	response to hypoxia	9887100\|15261140
Tgene	EP300	GO:0006110	regulation of glycolytic process	29775581
Tgene	EP300	GO:0006355	regulation of transcription, DNA-templated	15261140
Tgene	EP300	GO:0006473	protein acetylation	21030595\|24939902
Tgene	EP300	GO:0006475	internal protein amino acid acetylation	18722353
Tgene	EP300	GO:0010742	macrophage derived foam cell differentiation	26504087
Tgene	EP300	GO:0010976	positive regulation of neuron projection development	27256286
Tgene	EP300	GO:0016573	histone acetylation	25818647\|27256286
Tgene	EP300	GO:0018076	N-terminal peptidyl-lysine acetylation	12435739
Tgene	EP300	GO:0018393	internal peptidyl-lysine acetylation	17403783
Tgene	EP300	GO:0018394	peptidyl-lysine acetylation	23811396\|23962722
Tgene	EP300	GO:0031333	negative regulation of protein complex assembly	23962722
Tgene	EP300	GO:0034644	cellular response to UV	24939902
Tgene	EP300	GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	17403783
Tgene	EP300	GO:0043627	response to estrogen	11581164
Tgene	EP300	GO:0043923	positive regulation by host of viral transcription	16687403
Tgene	EP300	GO:0043969	histone H2B acetylation	23415232
Tgene	EP300	GO:0045721	negative regulation of gluconeogenesis	30193097
Tgene	EP300	GO:0045815	positive regulation of gene expression, epigenetic	25818647
Tgene	EP300	GO:0045944	positive regulation of transcription by RNA polymerase II	12586840\|18722353\|23811396
Tgene	EP300	GO:0051091	positive regulation of DNA-binding transcription factor activity	10518217\|25818647
Tgene	EP300	GO:0060765	regulation of androgen receptor signaling pathway	18487222
Tgene	EP300	GO:0061921	peptidyl-lysine propionylation	17267393
Tgene	EP300	GO:0090043	regulation of tubulin deacetylation	18722353
Tgene	EP300	GO:0140066	peptidyl-lysine crotonylation	25818647
Tgene	EP300	GO:0140067	peptidyl-lysine butyrylation	17267393\|29775581
Tgene	EP300	GO:1901224	positive regulation of NIK/NF-kappaB signaling	23811396
Tgene	EP300	GO:1905636	positive regulation of RNA polymerase II regulatory region sequence-specific DNA binding	23811396

Fusion gene breakpoints across KAT6A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across EP300 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Gene Sample Information

Fusion gene information from FusionGDB2.0.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerKB4	.	.	KAT6A	chr15	41798359		EP300	chr3	41521867

Top

Fusion ORF Analysis

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000265713

KAT6A

chr15

41798359

ENST00000263253

EP300

chr3

41521867

11088

3451

4579

4064

171

ENST00000396930

KAT6A

chr15

41798359

ENST00000263253

EP300

chr3

41521867

11220

3583

4711

4196

171

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

No-coding score

Coding score

Top

Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

>41203_41203_1_KAT6A-EP300_KAT6A_chr15_41798359_ENST00000265713_EP300_chr3_41521867_ENST00000263253_length(amino acids)=171AA_BP=
MILYPETLLKLLISLRRFWAETVGFSRYTIMSSRFLRDLELEIPFVPAIPLLGIYPKDYKSCCYKDTCTRMFIAAVFTIQRQERMMRPQS

--------------------------------------------------------------

>41203_41203_2_KAT6A-EP300_KAT6A_chr15_41798359_ENST00000396930_EP300_chr3_41521867_ENST00000263253_length(amino acids)=171AA_BP=
MILYPETLLKLLISLRRFWAETVGFSRYTIMSSRFLRDLELEIPFVPAIPLLGIYPKDYKSCCYKDTCTRMFIAAVFTIQRQERMMRPQS

--------------------------------------------------------------

Top

Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr15:/chr3:)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
KAT6A Q92794	EP300 Q09472
FUNCTION: Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML. {ECO:0000269\|PubMed:11742995, ECO:0000269\|PubMed:11965546, ECO:0000269\|PubMed:12771199, ECO:0000269\|PubMed:16387653, ECO:0000269\|PubMed:17925393, ECO:0000269\|PubMed:23431171}.	FUNCTION: Functions as histone acetyltransferase and regulates transcription via chromatin remodeling (PubMed:23415232, PubMed:23934153, PubMed:8945521). Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation (PubMed:23415232, PubMed:23934153, PubMed:8945521). Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-27' (H3K27ac) (PubMed:23911289). Also functions as acetyltransferase for non-histone targets, such as ALX1, HDAC1, PRMT1 or SIRT2 (PubMed:12929931, PubMed:16762839, PubMed:18722353). Acetylates 'Lys-131' of ALX1 and acts as its coactivator (PubMed:12929931). Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of p53/TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function (PubMed:18722353). Following DNA damage, forms a stress-responsive p53/TP53 coactivator complex with JMY which mediates p53/TP53 acetylation, thereby increasing p53/TP53-dependent transcription and apoptosis (PubMed:11511361, PubMed:15448695). Promotes chromatin acetylation in heat shock responsive HSP genes during the heat shock response (HSR), thereby stimulating HSR transcription (PubMed:18451878). Acetylates HDAC1 leading to its inactivation and modulation of transcription (PubMed:16762839). Acetylates 'Lys-247' of EGR2 (By similarity). Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2 (PubMed:12586840). Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Acetylates FOXO1 and enhances its transcriptional activity (PubMed:15890677). Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity (PubMed:12402037). Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCK or NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter (PubMed:14645221). Acetylates MTA1 at 'Lys-626' which is essential for its transcriptional coactivator activity (PubMed:16617102). Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity (PubMed:20955178). Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902). Acetylates MEF2D (PubMed:21030595). Acetylates and stabilizes ZBTB7B protein by antagonizing ubiquitin conjugation and degradation, this mechanism may be involved in CD4/CD8 lineage differentiation (PubMed:20810990). Acetylates GABPB1, impairing GABPB1 heterotetramerization and activity (By similarity). Acetylates PCK1 and promotes PCK1 anaplerotic activity (PubMed:30193097). Acetylates RXRA and RXRG (PubMed:17761950). In addition to protein acetyltransferase, can use different acyl-CoA substrates, such as (2E)-butenoyl-CoA (crotonyl-CoA), butanoyl-CoA (butyryl-CoA), 2-hydroxyisobutanoyl-CoA (2-hydroxyisobutyryl-CoA), lactoyl-CoA or propanoyl-CoA (propionyl-CoA), and is able to mediate protein crotonylation, butyrylation, 2-hydroxyisobutyrylation, lactylation or propionylation, respectively (PubMed:17267393, PubMed:25818647, PubMed:29775581, PubMed:31645732). Acts as a histone crotonyltransferase; crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors (PubMed:25818647). Histone crotonyltransferase activity is dependent on the concentration of (2E)-butenoyl-CoA (crotonyl-CoA) substrate and such activity is weak when (2E)-butenoyl-CoA (crotonyl-CoA) concentration is low (PubMed:25818647). Also acts as a histone butyryltransferase; butyrylation marks active promoters (PubMed:17267393). Catalyzes histone lactylation in macrophages by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription (PubMed:31645732). Acts as a protein-lysine 2-hydroxyisobutyryltransferase; regulates glycolysis by mediating 2-hydroxyisobutyrylation of glycolytic enzymes (PubMed:29775581). Functions as a transcriptional coactivator for SMAD4 in the TGF-beta signaling pathway (PubMed:25514493). {ECO:0000250\|UniProtKB:B2RWS6, ECO:0000269\|PubMed:10733570, ECO:0000269\|PubMed:11430825, ECO:0000269\|PubMed:11511361, ECO:0000269\|PubMed:11701890, ECO:0000269\|PubMed:12402037, ECO:0000269\|PubMed:12586840, ECO:0000269\|PubMed:12929931, ECO:0000269\|PubMed:14645221, ECO:0000269\|PubMed:15186775, ECO:0000269\|PubMed:15448695, ECO:0000269\|PubMed:15890677, ECO:0000269\|PubMed:16617102, ECO:0000269\|PubMed:16762839, ECO:0000269\|PubMed:17267393, ECO:0000269\|PubMed:17761950, ECO:0000269\|PubMed:18451878, ECO:0000269\|PubMed:18722353, ECO:0000269\|PubMed:18995842, ECO:0000269\|PubMed:20810990, ECO:0000269\|PubMed:21030595, ECO:0000269\|PubMed:23415232, ECO:0000269\|PubMed:23911289, ECO:0000269\|PubMed:23934153, ECO:0000269\|PubMed:24939902, ECO:0000269\|PubMed:25514493, ECO:0000269\|PubMed:25818647, ECO:0000269\|PubMed:29775581, ECO:0000269\|PubMed:30193097, ECO:0000269\|PubMed:31645732, ECO:0000269\|PubMed:8945521, ECO:0000305\|PubMed:20955178}.; FUNCTION: (Microbial infection) In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. {ECO:0000269\|PubMed:10545121, ECO:0000269\|PubMed:11080476}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

339_353

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

786_803

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

804_832

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

842_862

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

873_888

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

889_926

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

930_946

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

952_987

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

339_353

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

786_803

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

804_832

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

842_862

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

873_888

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

889_926

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

930_946

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

952_987

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

339_353

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

786_803

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

804_832

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

842_862

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

873_888

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

889_926

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

930_946

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

952_987

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

504_778

1013.0

2005.0

Domain

MYST-type HAT

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

95_171

1013.0

2005.0

Domain

H15

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

504_778

1013.0

2005.0

Domain

MYST-type HAT

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

95_171

1013.0

2005.0

Domain

H15

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

504_778

1013.0

2005.0

Domain

MYST-type HAT

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

95_171

1013.0

2005.0

Domain

H15

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1_144

1013.0

2005.0

Region

Note=Required for activation of RUNX1-1

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

334_375

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

441_464

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

488_778

1013.0

2005.0

Region

Note=Catalytic

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

52_166

1013.0

2005.0

Region

Note=Required for nuclear localization

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

645_649

1013.0

2005.0

Region

Acetyl-CoA binding

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

654_660

1013.0

2005.0

Region

Acetyl-CoA binding

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1_144

1013.0

2005.0

Region

Note=Required for activation of RUNX1-1

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

334_375

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

441_464

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

488_778

1013.0

2005.0

Region

Note=Catalytic

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

52_166

1013.0

2005.0

Region

Note=Required for nuclear localization

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

645_649

1013.0

2005.0

Region

Acetyl-CoA binding

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

654_660

1013.0

2005.0

Region

Acetyl-CoA binding

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1_144

1013.0

2005.0

Region

Note=Required for activation of RUNX1-1

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

334_375

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

441_464

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

488_778

1013.0

2005.0

Region

Note=Catalytic

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

52_166

1013.0

2005.0

Region

Note=Required for nuclear localization

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

645_649

1013.0

2005.0

Region

Acetyl-CoA binding

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

654_660

1013.0

2005.0

Region

Acetyl-CoA binding

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

206_265

1013.0

2005.0

Zinc finger

PHD-type 1

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

259_313

1013.0

2005.0

Zinc finger

PHD-type 2

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

537_562

1013.0

2005.0

Zinc finger

C2HC MYST-type

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

206_265

1013.0

2005.0

Zinc finger

PHD-type 1

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

259_313

1013.0

2005.0

Zinc finger

PHD-type 2

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

537_562

1013.0

2005.0

Zinc finger

C2HC MYST-type

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

206_265

1013.0

2005.0

Zinc finger

PHD-type 1

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

259_313

1013.0

2005.0

Zinc finger

PHD-type 2

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

537_562

1013.0

2005.0

Zinc finger

C2HC MYST-type

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1520_1547

243.0

2415.0

Compositional bias

Basic and acidic residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1548_1565

243.0

2415.0

Compositional bias

Basic residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1851_1886

243.0

2415.0

Compositional bias

Pro residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1909_1924

243.0

2415.0

Compositional bias

Pro residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1989_2010

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2100_2114

243.0

2415.0

Compositional bias

Pro residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2115_2163

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2206_2237

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2267_2310

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2311_2342

243.0

2415.0

Compositional bias

Pro residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2362_2385

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

753_811

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

827_849

243.0

2415.0

Compositional bias

Pro residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

857_895

243.0

2415.0

Compositional bias

Pro residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

896_926

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

941_971

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

974_1029

243.0

2415.0

Compositional bias

Basic and acidic residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1067_1139

243.0

2415.0

Domain

Bromo

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1287_1663

243.0

2415.0

Domain

CBP/p300-type HAT

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

566_645

243.0

2415.0

Domain

KIX

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1017_1029

243.0

2415.0

Region

Note=CRD1%3B mediates transcriptional repression

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1398_1400

243.0

2415.0

Region

Acetyl-CoA binding

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1410_1411

243.0

2415.0

Region

Acetyl-CoA binding

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1520_1578

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1572_1818

243.0

2415.0

Region

Note=Binding region for E1A adenovirus

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1833_1924

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1980_2010

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2094_2163

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2186_2237

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

2267_2385

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

482_518

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

729_1050

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1665_1713

243.0

2415.0

Zinc finger

ZZ-type

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1728_1809

243.0

2415.0

Zinc finger

TAZ-type 2

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

331_417

243.0

2415.0

Zinc finger

TAZ-type 1

- Not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1011_1029

1013.0

2005.0

Compositional bias

Basic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1124_1148

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1149_1171

1013.0

2005.0

Compositional bias

Basic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1201_1226

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1227_1245

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1271_1286

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1287_1320

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1321_1347

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1355_1369

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1390_1420

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1423_1437

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1478_1621

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1646_1701

1013.0

2005.0

Compositional bias

Pro residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1011_1029

1013.0

2005.0

Compositional bias

Basic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1124_1148

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1149_1171

1013.0

2005.0

Compositional bias

Basic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1201_1226

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1227_1245

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1271_1286

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1287_1320

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1321_1347

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1355_1369

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1390_1420

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1423_1437

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1478_1621

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1646_1701

1013.0

2005.0

Compositional bias

Pro residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1011_1029

1013.0

2005.0

Compositional bias

Basic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1124_1148

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1149_1171

1013.0

2005.0

Compositional bias

Basic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1201_1226

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1227_1245

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1271_1286

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1287_1320

1013.0

2005.0

Compositional bias

Acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1321_1347

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1355_1369

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1390_1420

1013.0

2005.0

Compositional bias

Basic and acidic residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1423_1437

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1478_1621

1013.0

2005.0

Compositional bias

Polar residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1646_1701

1013.0

2005.0

Compositional bias

Pro residues

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1461_1621

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1637_1721

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

1913_1948

1013.0

2005.0

Region

Note=Required for activation of RUNX1-2

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000265713

785_1445

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1461_1621

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1637_1721

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

1913_1948

1013.0

2005.0

Region

Note=Required for activation of RUNX1-2

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000396930

785_1445

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1461_1621

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1637_1721

1013.0

2005.0

Region

Disordered

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

1913_1948

1013.0

2005.0

Region

Note=Required for activation of RUNX1-2

Hgene

KAT6A

chr15:41798359

chr3:41521867

ENST00000406337

785_1445

1013.0

2005.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

196_234

243.0

2415.0

Compositional bias

Polar residues

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

11_17

243.0

2415.0

Motif

Nuclear localization signal

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

133_157

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

196_235

243.0

2415.0

Region

Disordered

Tgene

EP300

chr15:41798359

chr3:41521867

ENST00000263253

1_29

243.0

2415.0

Region

Disordered

Top

Fusion Protein Structures

PDB and CIF files of the predicted fusion proteins
* Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format.

Fusion protein PDB link (fusion AA seq ID in FusionPDB)	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	AA seq	Len(AA seq)

PDB file (17) >>>17.pdbFusion protein BP residue: CIF file (17) >>>17.cif	KAT6A	chr15	41798359		EP300	chr3	41521867		MILYPETLLKLLISLRRFWAETVGFSRYTIMSSRFLRDLELEIPFVPAIP LLGIYPKDYKSCCYKDTCTRMFIAAVFTIQRQERMMRPQSAMNIHSGWKC GSVLELECGGLIFMRYVHMLDCGVKGKKLQETGKECSGRKPRRVRCPANQ	171
3D view using mol* of 17 (AA BP:)

Top

pLDDT score distribution

pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.

KAT6A_pLDDT.png

EP300_pLDDT.png

pLDDT score distribution of the predicted fusion protein structures from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.

KAT6A_EP300_17_pLDDT.png (AA BP:)

Top

Ramachandran Plot of Fusion Protein Structure

Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide.

Fusion AA seq ID in FusionPDB and their Ramachandran plots

KAT6A_EP300_17.png

Top

Potential Active Site Information

The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite.

Fusion AA seq ID in FusionPDB

Site score

Size

D score

Volume

Exposure

Enclosure

Contact

Phobic

Philic

Balance

Don/Acc

Residues

Top

Potentially Interacting Small Molecules through Virtual Screening

The FDA-approved small molecule library molecules were subjected to virtual screening using the Glide.

Fusion AA seq ID in FusionPDB

ZINC ID

DrugBank ID

Drug name

Docking score

Glide gscore

Top

Drug information from DrugBank of the top 20 interacting small molecules.

ZINC ID

DrugBank ID

Drug name

Drug type

SMILES

Drug group

Top

Biochemical Features of Small Molecules

ADME (Absorption, Distribution, Metabolism, and Excretion) of drugs using QikProp(v3.9)

ZINC ID

mol_MW

dipole

SASA

FOSA

FISA

PISA

WPSA

volume

donorHB

accptHB

Human Oral Absorption

Percent Human Oral Absorption

Rule Of Five

Rule Of Three

Top

Drug Toxicity Information

Toxicity information of individual drugs using eToxPred

ZINC ID

Smile

Surface Accessibility

Toxicity

Top

Fusion Protein-Protein Interaction

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160)

Gene

PPI interactors

KAT6A

ING5, UBE2U, MAFK, BRPF1, HSPA4, TP53, EP300, MEAF6, HIST1H3A, HIST1H4A, RUNX1, CREBBP, ESR1, KMT2A, WDR5, HIST2H3C, ELAVL1, ATN1, ATXN1, RERE, H3F3C, HIST1H4I, HIST3H3, PML, SYMPK, AKT1, HIST4H4, CCNB1, CRK, RPL10, RNPS1, L1TD1, PHF14, TNRC6B, PNPLA8, RSF1, Myo1c, Rpl35, Tpx2, Srsf1, Tubgcp6, HEMGN, HNRNPL, KIAA1429, RANGAP1, BRD1, BRPF3, ING4, KAT7, JADE3, KAT6B, JADE2, JADE1, HIST1H2BO, HRG, CSNK2A2, APEX1, CENPA, DANCR, ZBTB2, CSNK2B, CSNK2A1, RFWD2, HSPD1, CMAS, HIST2H2BF, CASP2, TRIM65, HGH1, TTC4, PPP2R5C, OTUD3, DBNL, PIP4K2C, ATIC, NUDT12, B3GALTL, ATG4B, PABPN1, DEK, SF3A3,

Protein-protein interactors based on sequence similarity (STRING)

Gene	STRING network
KAT6A
EP300

- Retained interactions in fusion protein (protein functional feature from UniProt).

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost interactions due to fusion (protein functional feature from UniProt).

Partner	Gene	Hbp	Tbp	ENST	Strand	BPexon	TotalExon	Protein feature loci	*BPloci	TotalLen	Interaction lost with
Hgene	KAT6A	chr15:41798359	chr3:41521867	ENST00000265713		15	17	1517_1741	1013.0	2005.0	PML
Hgene	KAT6A	chr15:41798359	chr3:41521867	ENST00000396930		16	18	1517_1741	1013.0	2005.0	PML
Hgene	KAT6A	chr15:41798359	chr3:41521867	ENST00000406337		16	18	1517_1741	1013.0	2005.0	PML
Hgene	KAT6A	chr15:41798359	chr3:41521867	ENST00000265713		15	17	1517_1642	1013.0	2005.0	RUNX1-2
Hgene	KAT6A	chr15:41798359	chr3:41521867	ENST00000396930		16	18	1517_1642	1013.0	2005.0	RUNX1-2
Hgene	KAT6A	chr15:41798359	chr3:41521867	ENST00000406337		16	18	1517_1642	1013.0	2005.0	RUNX1-2
Tgene	EP300	chr15:41798359	chr3:41521867	ENST00000263253		1	31	2_139	243.0	2415.0	ALX1
Tgene	EP300	chr15:41798359	chr3:41521867	ENST00000263253		1	31	2_149	243.0	2415.0	RORA

Top

Related Drugs to KAT6A-EP300

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to KAT6A-EP300

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene	Tgene	Disease	Source	PMID
KAT6A	EP300	Breast Invasive Ductal Carcinoma	MyCancerGenome
KAT6A	EP300	Conventional Glioblastoma Multiforme	MyCancerGenome
KAT6A	EP300	Invasive Breast Carcinoma	MyCancerGenome
KAT6A	EP300	Lung Adenocarcinoma	MyCancerGenome
KAT6A	EP300	Prostate Adenocarcinoma	MyCancerGenome

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	KAT6A	C4225396	MENTAL RETARDATION, AUTOSOMAL DOMINANT 32	3	CTD_human;GENOMICS_ENGLAND;ORPHANET
Hgene	KAT6A	C4511003	Acute myeloid leukemia with t(8;16)(p11;p13) translocation	2	ORPHANET
Hgene	KAT6A	C0010606	Adenoid Cystic Carcinoma	1	CTD_human
Hgene	KAT6A	C0025149	Medulloblastoma	1	CTD_human
Hgene	KAT6A	C0033578	Prostatic Neoplasms	1	CTD_human
Hgene	KAT6A	C0205833	Medullomyoblastoma	1	CTD_human
Hgene	KAT6A	C0278510	Childhood Medulloblastoma	1	CTD_human
Hgene	KAT6A	C0278876	Adult Medulloblastoma	1	CTD_human
Hgene	KAT6A	C0376358	Malignant neoplasm of prostate	1	CTD_human
Hgene	KAT6A	C0751291	Desmoplastic Medulloblastoma	1	CTD_human
Hgene	KAT6A	C1275668	Melanotic medulloblastoma	1	CTD_human
Tgene	EP300	C0279626	Squamous cell carcinoma of esophagus	2	CTD_human
Tgene	EP300	C0001973	Alcoholic Intoxication, Chronic	1	PSYGENET
Tgene	EP300	C0005684	Malignant neoplasm of urinary bladder	1	CTD_human
Tgene	EP300	C0005695	Bladder Neoplasm	1	CTD_human
Tgene	EP300	C0006142	Malignant neoplasm of breast	1	CGI;CTD_human;UNIPROT
Tgene	EP300	C0007137	Squamous cell carcinoma	1	CTD_human
Tgene	EP300	C0007138	Carcinoma, Transitional Cell	1	CTD_human
Tgene	EP300	C0010606	Adenoid Cystic Carcinoma	1	CTD_human
Tgene	EP300	C0014170	Endometrial Neoplasms	1	CTD_human
Tgene	EP300	C0014518	Toxic Epidermal Necrolysis	1	CTD_human
Tgene	EP300	C0025202	melanoma	1	CTD_human
Tgene	EP300	C0028754	Obesity	1	CTD_human
Tgene	EP300	C0038325	Stevens-Johnson Syndrome	1	CTD_human
Tgene	EP300	C0079772	T-Cell Lymphoma	1	CTD_human
Tgene	EP300	C0149925	Small cell carcinoma of lung	1	CTD_human
Tgene	EP300	C0152013	Adenocarcinoma of lung (disorder)	1	CTD_human
Tgene	EP300	C0376634	Craniofacial Abnormalities	1	CTD_human
Tgene	EP300	C0476089	Endometrial Carcinoma	1	CTD_human
Tgene	EP300	C0678222	Breast Carcinoma	1	CGI;CTD_human
Tgene	EP300	C1257931	Mammary Neoplasms, Human	1	CTD_human
Tgene	EP300	C1274933	Drug-Induced Stevens Johnson Syndrome	1	CTD_human
Tgene	EP300	C1458155	Mammary Neoplasms	1	CTD_human
Tgene	EP300	C3150941	RUBINSTEIN-TAYBI SYNDROME 2	1	GENOMICS_ENGLAND
Tgene	EP300	C3658301	Mycoplasma-Induced Stevens-Johnson Syndrome	1	CTD_human
Tgene	EP300	C3658302	Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum	1	CTD_human
Tgene	EP300	C4704874	Mammary Carcinoma, Human	1	CTD_human